



Bellus
HEALTH

Annual and Special Meeting of Shareholders

May 9, 2017

Roberto Bellini

President and Chief Executive Officer

Twitter: @rbellini

Forward Looking Statements

*Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute “forward-looking statements” within the meaning of Canadian securities legislation and regulations. Such statements, based as they are on the current expectations of management, inherently involve numerous important risks, uncertainties and assumptions, known and unknown, many of which are beyond BELLUS Health Inc.’s control. Such risks factors include but are not limited to: the ability to obtain financing, the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which BELLUS Health Inc. does business, stock market volatility, fluctuations in costs, changes to the competitive environment due to consolidation, achievement of forecasted burn rate, potential payments/outcomes in relation to indemnity agreements and contingent value rights, achievement of forecasted pre-clinical and clinical trial milestones and that actual results may vary once the final and quality-controlled verification of data and analyses has been completed. In addition, the length of BELLUS Health Inc.’s drug candidates development process, their market size and commercial value, as well as the sharing of proceeds between BELLUS Health Inc. and its potential partners from potential future revenues, if any, are dependent upon a number of factors. Consequently, actual future results and events may differ materially from the anticipated results and events expressed in the forward-looking statements. The Company believes that expectations represented by forward-looking statements are reasonable, yet there can be no assurance that such expectations will prove to be correct. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These forward-looking statements speak only as of the date made, and BELLUS Health Inc. is under no obligation and disavows any intention to update publicly or revise such statements as a result of any new information, future event, circumstances or otherwise, unless required by applicable legislation or regulation. **Please see BELLUS Health Inc.’s public filings with the Canadian securities regulatory authorities, including the Annual Information Form, for further risk factors that might affect BELLUS Health Inc. and its business.***

- BLU-5937: potentially best-in-class drug for multi billion dollar market
 - Chronic cough affects ~10% of adults in U.S., large unmet need
 - Clinically validated target, clear and efficient development path
- Balanced portfolio: partner in three mid-stage programs
- Strong record of execution
 - Completed multiple transactions (in/out-licensing, partnering); attracted >\$100M in funding
 - Conducted global clinical studies, including Phase 3
- Cash runway to end of 2018

BLU-5937: Best-in-Class Potential



P2X3: Validated target for chronic cough

Merck acquired a P2X3 antagonist program in 2016 for US\$500M based on positive Phase 2 data

Problematic side effect profile with 50% patients experiencing taste disturbance

BLU-5937: Potentially best-in-class P2X3 antagonist

Potential for differentiated product profile with improved efficacy and reduced/no taste disturbance

Clear, efficient path to demonstrate superiority

BLU-5937 History

Developed at Astra Zeneca and then NEOMED Institute

Global rights licensed by BELLUS in February 2017

Low risk and superior profile targeting potential multi billion dollar drug class

Characteristics

Cough lasting ≥ 8 weeks, associated with:

- Pulmonary diseases (asthma, COPD, IPF)
- Extra-pulmonary disorders (post-nasal drip)
- Use of certain drugs (ACE inhibitors)
- No identifiable cause

Implications

Time and resource intensive for the healthcare system

- 38% of pulmonologist outpatient practice
- Resource intensive diagnosis for persistent/unexplained chronic cough

Chronic cough affects ~10% of the adult population

Major Impact on Patients

Physical complications

Sleep deprivation
Vomiting
Incontinence
Headache
Chest pain
Rib fracture

Social complications

Interference with
lifestyle, work &
leisure
Difficulty
conversing
Embarrassment
of coughing in
public

Psychosocial complications

Anxiety
Anger
Depression
Distress

Chronic cough has significant impact on patient quality of life

Few Treatment Options



Opioids

Some efficacy
Sedation/confusion
Constipation and nausea
Potential for addiction

Gabapentin/Pregabalin

Limited and variable efficacy
Sedation/confusion
Poor memory
Weight gain

OTC Products

Very limited efficacy

No novel treatment approved for chronic cough in 50 years

Cause: Hypersensitive Cough Reflex

Coughing trigger
(ex. asthma attack)




Cellular damage activates
P2X3 receptors in airway



Airway hyper-excitability



Chronic cough



P2X3 receptors found in peripheral nervous system, involved in cough as well as pain and taste

P2X3 Receptor: Clinically Validated Target

Mildly selective P2X3 benchmark compound AF-219 (acquired by Merck) has sub-ideal profile :

Meaningful Effect

50 to 75%

reduction in cough frequency

Problematic Side Effect

50 to 100%

of patients experience taste disturbance
(likely due to low P2X3 selectivity)

Abdulqawi et al., 2016. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. Vol 385, No 9974 pp. 1198-1205.
Kitt et al., 2016. A Phase 2 Dose-Escalation Study with AF-219, a P2X3 Antagonist for the Treatment of Chronic Cough. American Thoracic Society 2016 International Conference - San Francisco.

Opportunity for *highly selective* P2X3 antagonist with better efficacy/safety profile to become class leader

BLU-5937: Best-in-Class Profile



Dosed
Orally

High
Potency and Selectivity
for P2X3


Zero
safety findings of
concern

Broad and
comprehensive IP to
2034

Kg
scale CMC

Strong drug candidate profile with potential to be best in P2X3 class

Preclinical Efficacy: Cough Response




Treatments (control, BLU-5937) were administered orally (p.o.) two hours prior to tussive agent exposure: citric acid (0.1 M, aerosol) and histamine (0.6 mM, aerosol); n=6 animals (guinea pig) per group *p<0.05


Dose-dependent reduction in cough frequency in guinea pig model

Importance of Selectivity on Taste


Mechanism



Competitor Approach



BELLUS Approach




Legend ■ P2X3 ■ P2X2/3 ● Drug (P2X3 Antagonist)

High selectivity of BLU-5937 for P2X3 could limit or eliminate taste alteration side effect without compromising effect on cough

Large Addressable Market



275M U.S. adults



27.5M patients

2.75M have unexplained/refractory chronic cough



6.3M

estimated addressable patients in major pharma markets

Major pharma markets include the U.S., Europe top five countries and Japan

Song et al., 2015. The global epidemiology of chronic cough in adults: a systematic review and meta-analysis. Eur Respir J. Vol 55 pp. 1479-1481

Zanasi et al., 2014. Chronic and unexplained cough. (Published online) Vol 4, No 3 pp. 159-164

BLU-5937: Key Development Milestones

2017	2018	2019/2020
IND-enabling studies Complete preclinical study package for regulatory submission to start dosing patients	Phase I: assess dose and taste effect Assess safety, tolerability, PK, effect on taste in healthy subjects Single ascending dose and multiple ascending dose studies	Phase II: demonstrate anti-cough effect Assess safety, PK and anti-cough effects in patients suffering from chronic refractory cough Dose response study with crossover design

Value creating milestones throughout development path

Pipeline Overview



	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
BLU-5937 Chronic Cough	Wholly-owned			
KIACTA Sarcoidosis	Partnered IP (Revenue Share)			
AMO-01 Fragile X Syndrome	Partnered IP (Revenue Share & Royalty)			
ALZ-801 Alzheimer's Disease	Partnered IP (Revenue Share & Royalty)			

Strong core project, balanced pipeline, multiple prospects

Partnered Programs



KIACTA™ for Sarcoidosis (Auveo Therapeutics)

Principally respiratory disease affecting ~100K in U.S.
IP licensed in 2009 with double digit revenue share
Reduces key inflammatory markers mediated by amyloid A
Auveo to confirm plans to enter Phase 2/3 study in 2017

AMO-01 for Fragile X Syndrome (AMO Pharma)

Genetic disorder affecting ~180K in U.S.
IP licensed in 2014 for single-digit royalty/small revenue share
Reverses disease abnormalities in preclinical model
Start of Phase 2 expected in 2017

ALZ-801 for Alzheimer's disease (AD) (Alzheon Inc)

IP licensed in 2013 for mid single-digit royalty/revenue share
Inhibitor of amyloid aggregation
Preparing for Phase 3 for homozygous Apo E AD patients

Financial Highlights



Stock Information (April 28, 2017)

Ticker	TSX: BLU
Shares (basic)	66.9M
Shares (fully diluted)	71.7M
Market Capitalization	~\$20M

Key Financials¹

Cash	\$7.5M
Cash Runway	Q4 2018








Fully Diluted Shareholder Ownership

Bellini Family	~25%
Power Corporation	~25%

¹as at December 31, 2016 and *pro forma* to upfront considerations of Thallion and NEOMED transactions

Governance and Shareholders



Board Slate			
Dr. Francesco Bellini (Chair) 	Franklin Berger 	Pierre Larochelle 	
Youssef Bennani 	Joseph Rus 	Dr. Martin Tolar 	Roberto Bellini 
Management			
Roberto Bellini, President and Chief Executive Officer			
Dr. Denis Garceau, Senior Vice President, Drug Development			
François Desjardins, Vice President, Finance			
Tony Matzouranis, Vice President, Business Development			

Multiple Upcoming Milestones to Drive Value



Past Execution

- ✓ Attracted >\$100M to funding projects
- ✓ Executed multiple global clinical studies including Phase 3
- ✓ Completed multiple transactions (in-licensing, partnering, out-licensing)

Milestones (12 months)

Execution of BLU-5937 plan in chronic cough:

- IND-enabling studies
- Market assessment
- Further animal POC data

Progress in other projects

- KIIACTA™ Phase 2/3, Sarcoidosis
- AMO-01 Phase 2 in Fragile X
- Alzheon financing

Developing promising candidates to value inflection points



Bellus
HEALTH

Connect With Us

- Follow us on Twitter: @BELLUSHealth
- Join our LinkedIn group
- Read our blog @ www.bellushealth.com
- Join our mailing list